乌鸦传媒

<乌鸦传媒 class="page-title">Meeting Coverage

ASCO Expert Roundtable: Breast Cancer

<乌鸦传媒 class="page-description">Expert Roundtable from the American Society of Clinical Oncology
Olaparib Shows 'Unbelievable' Response Rate in MBC With PALB2 or BRCA Mutations

Expanded trial data confirm potentially practice-changing results

image
<乌鸦传媒 class="section_title">Latest ASCO Expert Roundtable: Breast Cancer Meeting Coverage
Ribociclib Reduces Risk of Recurrence for High-Risk Node-Negative Breast Cancer

Hope Rugo, MD, leads a discussion with Joyce O'Shaughnessy, MD, and Sara Tolaney, MD

July 1, 2024
Treating Advanced Breast Cancer After Progression on CDK4/6 Inhibitors

Results from postMONARCH offer one path

June 24, 2024
Are T-DXd Results in HER2-Low/Ultralow Breast Cancer Practice-Changing?

Hope Rugo, MD, leads a discussion with Joyce O'Shaughnessy, MD, and Sara Tolaney, MD, MPH

June 18, 2024
'Reassuring' New Breast Cancer Survival Data on Fulvestrant Plus CDK4/6 Inhibitors

Our expert roundtable discusses the overall survival updates from PALOMA-3 and MONALEESA-3

July 14, 2021
New Developments in Triple-Negative Breast Cancer Therapies

Our expert roundtable discusses GeparNuevo and the future of treatments for TNBC

July 7, 2021
New Data on Role of Gene Assays in Breast Cancer Treatment

Our expert roundtable discusses which patients could benefit from extended endocrine therapy

June 30, 2021
PARP Inhibitors for Early, BRCA-Mutant Breast Cancer

Our expert roundtable discusses the OlympiA and NEOTALA trials

June 23, 2021
<乌鸦传媒 class="section_title"> Latest Oncology/Hematology Meeting Coverage